Subclinical inflammation and joint damage progression in patients with early RA fulfilling 2011 vs 2022 ACR/EULAR Boolean remission criteria: data from the ARCTIC study

Patients on a bDMARD †, n (%) 15 ( 14) 3 ( 12) 15 (13) 3 (20) NA NA *Mean difference based on the linear mixed model with both 12-month and 24-month data.†All bDMARDs were TNF-alfa inhibitors.bDMARDs, biological disease-modifying antirheumatic drugs; DAS,